Medochemie has nine manufacturing plants in Cyprus, one in The Netherlands and one (soon to be two) in Vietnam. The company has 3,800 marketing authorization licenses for 630 different pharmaceutical products, for over 10 therapeutic categories.

The company will invest an estimated US$16 million in building the facility at an industrial park in Binh Duong Province, about 30 km outside Ho Chi Minh City, according to reports in the Vietnamese press. The facility is being built to World Health Organization and European Union good manufacturing practice (GMP) standards.

No information has been released on the products that will be manufactured at the new site.

Vietnam reflects a pattern across Southeast Asia, with its fast-growing, young population and uninsured majority, representing a great opportunity for generics in the pharmaceutical industry, according to Mr Rhett Hemedes, Head of OTC Marketing, Great Eastern Drug Co [1].

Although the generics market is currently quite small, improved access to medicines in the region means that it is growing rapidly and is expected to reach US$3.9 billion by 2016.

It is a prediction that has attracted many multinational pharma companies to the area [1]. Sanofi currently has three sites in Vietnam, where it makes specialty pharmaceuticals and consumer health products.

Related article
Teva outlines expansion plans in Asia

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. Southeast Asian generics market to reach US$3.9 billion by 2016 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Apr 27]. Available from: www.gabionline.net/Generics/General/Southeast-Asian-generics-market-to-reach-US-3.9-billion-by-2016 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.